Interaction more likely in certain predisposed pts. only.prochlorperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.epinephrine racemicprochlorperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.eribulineribulin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.estazolamestazolam and prochlorperazine both increase sedation. Use Caution/Monitor.ethanolprochlorperazine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and prochlorperazine both increase sedation. Use Caution/Monitor.fenfluramineprochlorperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.fesoterodinefesoterodine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.fesoterodine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fingolimodfingolimod and prochlorperazine both decrease QTc interval. Use Caution/Monitor.flavoxateflavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainideprochlorperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetinefluoxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.prochlorperazine and fluoxetine both increase QTc interval. Use Caution/Monitor.fluphenazinefluphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.fluphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and prochlorperazine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and prochlorperazine both increase QTc interval. Use Caution/Monitor.formoterolprochlorperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnetprochlorperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.ganaxoloneprochlorperazine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and prochlorperazine both decrease QTc interval. Use Caution/Monitor.glycopyrrolateprochlorperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrrolate inhaledglycopyrrolate inhaled decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.glycopyrrolate inhaled decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrronium tosylate topicalglycopyrronium tosylate topical, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetrongranisetron and prochlorperazine both decrease QTc interval. Use Caution/Monitor.guanfacineguanfacine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.haloperidolhaloperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.haloperidol and prochlorperazine both increase sedation. Use Caution/Monitor.henbanehenbane decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.henbane decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.homatropinehomatropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.homatropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hydromorphonehydromorphone and prochlorperazine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and prochlorperazine both increase sedation. Use Caution/Monitor.hydroxyzine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.hyoscyamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine sprayprochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.iloperidoneiloperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and prochlorperazine both increase sedation. Use Caution/Monitor.imipramineprochlorperazine and imipramine both increase QTc interval. Use Caution/Monitor.prochlorperazine and imipramine both increase sedation. Use Caution/Monitor.incobotulinumtoxinAprochlorperazine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.insulin degludecprochlorperazine decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin degludec/insulin aspartprochlorperazine decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin inhaledprochlorperazine decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.ipratropiumipratropium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.ipratropium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.isofluraneisoflurane and prochlorperazine both decrease QTc interval. Use Caution/Monitor.isoproterenolprochlorperazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.ketamineketamine and prochlorperazine both increase sedation. Use Caution/Monitor.ketotifen, ophthalmicprochlorperazine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lapatinibprochlorperazine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, prochlorperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantlemborexant, prochlorperazine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuterolprochlorperazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacinprochlorperazine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levorphanollevorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.liraglutideprochlorperazine, liraglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.lisdexamfetamineprochlorperazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.lithiumlithium, prochlorperazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.lithium and prochlorperazine both decrease QTc interval. Use Caution/Monitor.lofepramineprochlorperazine and lofepramine both increase sedation. Use Caution/Monitor.lofexidineprochlorperazine and lofexidine both increase sedation. Use Caution/Monitor.loprazolamloprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.lorazepamlorazepam and prochlorperazine both increase sedation. Use Caution/Monitor.lormetazepamlormetazepam and prochlorperazine both increase sedation. Use Caution/Monitor.loxapineloxapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine and prochlorperazine both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and prochlorperazine both increase sedation. Use Caution/Monitor.lumefantrinelumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lurasidonelurasidone, prochlorperazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilineprochlorperazine and maprotiline both increase QTc interval. Use Caution/Monitor.prochlorperazine and maprotiline both increase sedation. Use Caution/Monitor.marijuanaprochlorperazine and marijuana both increase sedation. Use Caution/Monitor.meclizinemeclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.meclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.melatoninprochlorperazine and melatonin both increase sedation. Use Caution/Monitor.meperidinemeperidine and prochlorperazine both increase sedation. Use Caution/Monitor.meprobamateprochlorperazine and meprobamate both increase sedation. Use Caution/Monitor.metaproterenolprochlorperazine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonemetaxalone and prochlorperazine both increase sedation. Use Caution/Monitor.metforminprochlorperazine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia.methadoneprochlorperazine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.methadone and prochlorperazine both increase sedation. Use Caution/Monitor.methamphetamineprochlorperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, methamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.methocarbamolmethocarbamol and prochlorperazine both increase sedation. Use Caution/Monitor.methoxsalenmethoxsalen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.methscopolaminemethscopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.methscopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.methylenedioxymethamphetamineprochlorperazine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, methylenedioxymethamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.methylphenidateprochlorperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.metoclopramideprochlorperazine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.midazolammidazolam and prochlorperazine both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrineprochlorperazine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, midodrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.mirtazapineprochlorperazine and mirtazapine both increase sedation. Use Caution/Monitor.mirtazapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.modafinilprochlorperazine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphinemorphine and prochlorperazine both increase sedation. Use Caution/Monitor.motherwortprochlorperazine and motherwort both increase sedation. Use Caution/Monitor.moxonidineprochlorperazine and moxonidine both increase sedation. Use Caution/Monitor.nabiloneprochlorperazine and nabilone both increase sedation. Use Caution/Monitor.nalbuphinenalbuphine and prochlorperazine both increase sedation. Use Caution/Monitor.norepinephrineprochlorperazine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.prochlorperazine, norepinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.nortriptylineprochlorperazine and nortriptyline both increase QTc interval. Use Caution/Monitor.prochlorperazine and nortriptyline both increase sedation. Use Caution/Monitor.ofloxacinprochlorperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineolanzapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.olanzapine and prochlorperazine both increase sedation. Use Caution/Monitor.olanzapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor.oliceridineoliceridine, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).onabotulinumtoxinAonabotulinumtoxinA decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.onabotulinumtoxinA decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.opium tinctureopium tincture and prochlorperazine both increase sedation. Use Caution/Monitor.orphenadrineorphenadrine and prochlorperazine both increase sedation. Use Caution/Monitor.oxaliplatinoxaliplatin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.oxazepamoxazepam and prochlorperazine both increase sedation. Use Caution/Monitor.oxybutyninoxybutynin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oxybutynin topicaloxybutynin topical decreases levels of prochlorperazine by inhibition of